Dr. Steven Carr, a senior scientific leader in protein biochemistry and proteomics leads the Proteomics platform at the Broad Institute. In this capacity, Dr. Carr and his group work with biologists to systematically identify proteins and their modifications – such as phosphorylation, whose abundance or form is modulated by disease or drug action – as well as define physical and functional associations of protein constituents of regulatory and signaling pathways involved in health and disease. These studies involve analysis of complex biological specimens, such as tumor tissues or patient blood, using protein chemistry and advanced separation methods together with state-of-the-art mass spectrometry. For the last 25 years, Dr. Carr’s research has focused on applying and developing proteomics methods in order to understand the mechanism of action of drug candidates and build an understanding of protein targets and their roles in disease. In particular, he is noted for developing methods for selective enrichment, detection and quantitation of posttranslational modifications, such as phosphorylation and glycosylation, in the proteome. He has over 125 publications on development and use of proteomics and biological mass spectrometry. Dr. Carr received his B.S. in 1976 from Union College and Ph.D. from MIT in 1980. After four years of postdoctoral training at Harvard Medical School and MIT, he joined SmithKline Pharmaceuticals (now GlaxoSmithKline), becoming director of Computational and Structural Sciences in 1997. Most recently he led protein science and proteomics groups at Millennium Pharmaceuticals in Cambridge, MA, prior to joining the Broad in 2004.